论文部分内容阅读
1952年Conley等首先发现SLE(系统性红斑狼疮)患者血浆中的所谓“狼疮抗凝物质”(LA)引起一种血液凝固缺陷。后来明确了LA是一种抗体,是凝血激酶复合物的抑制物,在体外它可延长白陶土部分凝血活酶时间(KPTT),体内它仍有高凝作用。作者研究了60例SLE和其它结缔组织病患者,探讨了LA与患者临床和血清学发现间的关系。
In 1952 Conley first discovered that the so-called “lupus anticoagulant” (LA) in the plasma of patients with systemic lupus erythematosus (SLE) caused a blood clotting defect. It was later clarified that LA is an antibody that is an inhibitor of the thromboxane kinase complex and prolongs the kaolin partial thromboplastin time (KPTT) in vitro and that it still has hypercoagulability in vivo. The authors studied 60 patients with SLE and other connective tissue diseases and explored the relationship between LA and clinical and serological findings.